- Home
- XBIO vs YOSH Comparison
XBIO vs YOSH Comparison
Compare XBIO & YOSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- YOSH
- Stock Information
- Founded
- XBIO N/A
- YOSH 2016
- Country
- XBIO United States
- YOSH United States
- Employees
- XBIO N/A
- YOSH N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- YOSH Restaurants
- Sector
- XBIO Health Care
- YOSH Consumer Discretionary
- Exchange
- XBIO Nasdaq
- YOSH Nasdaq
- Market Cap
- XBIO 5.8M
- YOSH 6.4M
- IPO Year
- XBIO N/A
- YOSH 2022
- Fundamental
- Price
- XBIO $3.66
- YOSH $3.04
- Analyst Decision
- XBIO Hold
- YOSH
- Analyst Count
- XBIO 1
- YOSH 0
- Target Price
- XBIO N/A
- YOSH N/A
- AVG Volume (30 Days)
- XBIO 30.0K
- YOSH 55.4K
- Earning Date
- XBIO 11-12-2024
- YOSH 11-22-2024
- Dividend Yield
- XBIO N/A
- YOSH N/A
- EPS Growth
- XBIO N/A
- YOSH N/A
- EPS
- XBIO N/A
- YOSH N/A
- Revenue
- XBIO $2,523,427.00
- YOSH $10,662,741.00
- Revenue This Year
- XBIO N/A
- YOSH N/A
- Revenue Next Year
- XBIO N/A
- YOSH N/A
- P/E Ratio
- XBIO N/A
- YOSH N/A
- Revenue Growth
- XBIO 7.15
- YOSH 18.50
- 52 Week Low
- XBIO $2.78
- YOSH $2.73
- 52 Week High
- XBIO $5.20
- YOSH $13.86
- Technical
- Relative Strength Index (RSI)
- XBIO 45.78
- YOSH 29.54
- Support Level
- XBIO $3.58
- YOSH $2.73
- Resistance Level
- XBIO $4.60
- YOSH $5.25
- Average True Range (ATR)
- XBIO 0.41
- YOSH 0.91
- MACD
- XBIO -0.02
- YOSH -0.16
- Stochastic Oscillator
- XBIO 7.48
- YOSH 7.91
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.